Corient Private Wealth
NAGE

Corient Private Wealth’s Niagen Bioscience NAGE Stock Holding History

Corient Private Wealth’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Sell
38,124
-2,377
-6% -$9.65K ﹤0.01% 2903
2026
Q1 		$179K Buy
40,501
+9,128
+29% +$49.3K ﹤0.01% 2585
2025
Q4 		$200K Buy
+31,373
New +$218K ﹤0.01% 2433

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Corient Private Wealth's NAGE Position: Q2 2026 in Review

Corient Private Wealth reduced its Niagen Bioscience (NAGE) stake by 5.9% in Q2 2026, selling an estimated $9.65K and leaving 38,124 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Corient Private Wealth first reported a position in NAGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $200K in Q4 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Corient Private Wealth held 38,124 shares of Niagen Bioscience worth $122K as of Q2 2026.
  • Corient Private Wealth sold 2,377 Niagen Bioscience shares in Q2 2026, an estimated $9.65K.
  • Niagen Bioscience made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2903 holding.
  • Corient Private Wealth first reported a position in Niagen Bioscience in Q4 2025 and has held it in 3 quarters since.
  • Corient Private Wealth's Niagen Bioscience position peaked at $200K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.